JP Morgan 2026: Medable's New AI Agent Automates Trial Master File Processes, Slashing Regulatory Bottlenecks
Published: 23 Mar 2026
Author: Precedence Research
Medable Launches AI Agent to Streamline TMF Processes. This tool alleviates the burden on human resources, addressing a major labor cost in clinical research. CEO Michelle Longmire will showcase the AI agent at the JP Morgan Health event.
Medable Debuts First Agentic AI for End-to-End Clinical Document Management
Medable Inc. has unveiled its TMF Agent, an Artificial Intelligence-driven tool designed to simplify trial document management. This innovation enhances quality and consistency while minimizing manual labor. Built on Medable’s Agent Studio, the first agentic AI platform in clinical development, it addresses the challenge of managing thousands of documents monthly, with over 95% still processed manually, leading to inefficiencies and backlogs.
According to Precedence Research, the Electronic Trial Master File System Market size accounted for USD 1.46 billion in 2025 and is predicted to increase from USD 1.65 billion in 2026 to approximately USD 5.00 billion by 2035, expanding at a CAGR of 13.10% from 2026 to 2035 as demand grows for the adoption of cloud-based solutions, increased R&D spending, and the rising prevalence of decentralized, complex clinical trials.
Medable’s new TMF Agent effectively manages TMF workflows by autonomously collecting documents from shared inboxes, drives, and other sources. It categorizes files, extracts metadata, and prepares them for human review before submitting them with one click to popular eTMF systems like Veeva Vault, Wingspan, and OpenText. Notably, Medable agents are system-agnostic, which means they can easily integrate into existing clinical workflows. They also include human-in-the-loop checkpoints for validation, quality assurance, and audit traceability, ensuring confidence and compliance.
Medable Declares "Agentic Era" for Clinical Trials with New AI TMF Tool
"We are using AI to improve quality and remove bottlenecks in clinical development, allowing skilled professionals to focus on more strategic tasks that push clinical development forward," said Dr. Michelle Longmire, CEO and Co-Founder of Medable. "Medable agents enhance trial systems by reducing the friction between document management and regulatory submission. We will continue to develop agents that address the toughest challenges in clinical trials while also enabling customers to create their own using Studio."
Dr. Michelle Longmire is set to speak at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Medable will also showcase its agentic portfolio to select partners during the event and will be open for partnership discussions and product demonstrations upon request.
A recent report by Precedence Research highlights that the Electronic Trial Master File System market is benefiting from the rapid digitization of clinical trials, stringent regulatory compliance requirements, and the rising need for real-time document accessibility.